Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Derek De-Rui Huang

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2026
Beyond PACIFIC: Rethinking Consolidation in Molecularly Defined Stage III NSCLCHsin-Tuan Huang, Derek De-Rui Huang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 6, 2026
Decoding Variants in EGFR Exon 20 Insertions: Guiding Therapy Beyond a One-Size-Fits-All ApproachMing-Hsuan Wu, Derek De-Rui Huang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2025
Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerDerek De-Rui Huang, James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2025
Erratum: Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerDerek De-Rui Huang, James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Reply to: Afatinib, Dose Reduction, and Pseudo-Acute Kidney InjuryDerek De-Rui Huang, James Chih-Hsin Yang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2020
Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor-the End or Beginning?Derek De-Rui Huang, James Chih-Hsin Yang
Cancer Cell|February 13, 2024
Re-inventing a better wheel? Serplulimab for squamous cell lung cancerDerek De-Rui Huang, James Chih-Hsin Yang
Journal of the Formosan Medical Association = Taiwan Yi Zhi|January 29, 2025
Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumorsYen-Lin Huang, Chia-Chi Hsu, Derek De-Rui Huang, et al.
Cancer Treatment Reviews|January 3, 2026
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?Seng Wee Cheo, Molly S C Li, Derek De-Rui Huang, et al.
Journal of Biomedical Science|October 9, 2025
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLCChia-Chi Hsu, Derek De-Rui Huang, Wei-Hsun Hsu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2026
Beyond PACIFIC: Rethinking Consolidation in Molecularly Defined Stage III NSCLCHsin-Tuan Huang, Derek De-Rui Huang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 6, 2026
Decoding Variants in EGFR Exon 20 Insertions: Guiding Therapy Beyond a One-Size-Fits-All ApproachMing-Hsuan Wu, Derek De-Rui Huang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 25, 2025
Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerDerek De-Rui Huang, James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 9, 2025
Erratum: Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerDerek De-Rui Huang, James Chih-Hsin Yang
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 24, 2025
Reply to: Afatinib, Dose Reduction, and Pseudo-Acute Kidney InjuryDerek De-Rui Huang, James Chih-Hsin Yang
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2020
Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor-the End or Beginning?Derek De-Rui Huang, James Chih-Hsin Yang
Cancer Cell|February 13, 2024
Re-inventing a better wheel? Serplulimab for squamous cell lung cancerDerek De-Rui Huang, James Chih-Hsin Yang
Journal of the Formosan Medical Association = Taiwan Yi Zhi|January 29, 2025
Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumorsYen-Lin Huang, Chia-Chi Hsu, Derek De-Rui Huang, et al.
Cancer Treatment Reviews|January 3, 2026
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far?Seng Wee Cheo, Molly S C Li, Derek De-Rui Huang, et al.
Journal of Biomedical Science|October 9, 2025
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLCChia-Chi Hsu, Derek De-Rui Huang, Wei-Hsun Hsu, et al.
Pageof 2